

# Pamala A Jacobson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4380772/publications.pdf>

Version: 2024-02-01

91  
papers

1,972  
citations

218677  
26  
h-index

276875  
41  
g-index

94  
all docs

94  
docs citations

94  
times ranked

2805  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium. <i>Transplantation</i> , 2011, 91, 300-308.	1.0	151
2	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 5074-5082.	1.4	143
3	Dosing equation for tacrolimus using genetic variants and clinical factors. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 948-957.	2.4	140
4	NPHP1 (Nephrocystin-1) Gene Deletions Cause Adult-Onset ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1772-1779.	6.1	74
5	Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 486-500.	4.7	71
6	Glutathione S-transferase A1 Genetic Variants Reduce Busulfan Clearance in Children Undergoing Hematopoietic Cell Transplantation. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 1052-1062.	2.0	65
7	Genetic and Clinical Determinants of Early, Acute Calcineurin Inhibitor-Related Nephrotoxicity. <i>Transplantation</i> , 2012, 93, 624-631.	1.0	62
8	Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation. <i>Transplantation</i> , 2011, 91, 309-316.	1.0	52
9	Concept and design of a genome-wide association genotyping array tailored for transplantation-specific studies. <i>Genome Medicine</i> , 2015, 7, 90.	8.2	49
10	Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics. <i>Transplant International</i> , 2013, 26, 982-989.	1.6	47
11	Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 766-769.	4.7	46
12	Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1047-1056.	1.9	43
13	Single-Nucleotide Polymorphisms, Acute Rejection, and Severity of Tubulitis in Kidney Transplantation, Accounting for Center-to-Center Variation. <i>Transplantation</i> , 2010, 90, 1401-1408.	1.0	37
14	Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 926-933.	2.0	35
15	Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups. <i>American Journal of Transplantation</i> , 2019, 19, 2795-2804.	4.7	35
16	Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 304-311.	2.0	34
17	Mycophenolate Pharmacokinetics and Association with Response to Acute Graft-versus-Host Disease Treatment from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 421-429.	2.0	32
18	Validation of tacrolimus equation to predict troughs using genetic and clinical factors. <i>Pharmacogenomics</i> , 2012, 13, 1141-1147.	1.3	32

#	ARTICLE	IF	CITATIONS
19	Quantitative High-Performance Liquid Chromatography~Electrospray Ionization Tandem Mass Spectrometry Analysis of Bis-<i>N</i>-7-Guanine DNA~DNA Cross-Links in White Blood Cells of Cancer Patients Receiving Cyclophosphamide Therapy. <i>Analytical Chemistry</i> , 2010, 82, 3650-3658.	6.5	31
20	Multigene predictors of tacrolimus exposure in kidney transplant recipients. <i>Pharmacogenomics</i> , 2015, 16, 841-854.	1.3	31
21	Tacrolimus trough and dose intra~patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. <i>Clinical Transplantation</i> , 2018, 32, e13424.	1.6	30
22	Highly Variable Mycophenolate Mofetil Bioavailability Following Nonmyeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 6-12.	2.0	29
23	A Limited Sampling Model for Estimation of Total and Unbound Mycophenolic Acid (MPA) Area Under the Curve (AUC) in Hematopoietic Cell Transplantation (HCT). <i>Therapeutic Drug Monitoring</i> , 2006, 28, 394-401.	2.0	28
24	Validation of single nucleotide polymorphisms associated with acute rejection in kidney transplant recipients using a large multi-center cohort. <i>Transplant International</i> , 2011, 24, 1231-1238.	1.6	27
25	Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor~Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2025-2030.	2.0	27
26	Genetics of acute rejection after kidney transplantation. <i>Transplant International</i> , 2018, 31, 263-277.	1.6	27
27	Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 463-475.	2.4	26
28	Formation of cyclophosphamide specific DNA adducts in hematological diseases. <i>Pediatric Blood and Cancer</i> , 2012, 58, 708-714.	1.5	24
29	Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 628-639.	2.0	24
30	Urinary microbiome associated with chronic allograft dysfunction in kidney transplant recipients. <i>Clinical Transplantation</i> , 2018, 32, e13436.	1.6	24
31	Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. <i>Pharmacogenomics</i> , 2018, 19, 175-184.	1.3	23
32	Stability of tacrolimus in an extemporaneously compounded oral liquid. <i>American Journal of Health-System Pharmacy</i> , 1997, 54, 178-180.	1.0	22
33	Population Pharmacokinetics of Unbound Mycophenolic Acid in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1665-1675.	2.0	22
34	Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 519-525.	3.0	22
35	Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. <i>Translational Research</i> , 2016, 175, 103-115.e4.	5.0	22
36	Differentially Expressed Gene Transcripts Using RNA Sequencing from the Blood of Immunosuppressed Kidney Allograft Recipients. <i>PLoS ONE</i> , 2015, 10, e0125045.	2.5	20

#	ARTICLE	IF	CITATIONS
37	Higher Mycophenolate Dose Requirements in Children Undergoing Hematopoietic Cell Transplant (HCT). <i>Journal of Clinical Pharmacology</i> , 2008, 48, 485-494.	2.0	19
38	CRISPR/Cas9 Genetic Modification of <i>CYP3A5</i> *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism. <i>Drug Metabolism and Disposition</i> , 2017, 45, 957-965.	3.3	18
39	Telomere Length of Recipients and Living Kidney Donors and Chronic Graft Dysfunction in Kidney Transplants. <i>Transplantation</i> , 2014, 97, 325-329.	1.0	18
40	Tacrolimus Elimination in Four Patients With a <i>CYP3A5</i> *3/ <i>CYP3A4</i> *22 Genotype Combination. <i>Pharmacotherapy</i> , 2018, 38, e46-e52.	2.6	17
41	Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies. <i>Transplantation</i> , 2019, 103, 1131-1139.	1.0	17
42	Analysis of 75 Candidate SNPs Associated With Acute Rejection in Kidney Transplant Recipients: Validation of rs2910164 in MicroRNA MIR146A. <i>Transplantation</i> , 2019, 103, 1591-1602.	1.0	16
43	Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes. <i>Nature Medicine</i> , 2022, 28, 999-1005.	30.7	15
44	Mycophenolate Mofetil in Islet Cell Transplant: Variable Pharmacokinetics but Good Correlation Between Total and Unbound Concentrations. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 901-909.	2.0	14
45	Inflammation in the setting of chronic allograft dysfunction post kidney transplant: phenotype and genotype. <i>Clinical Transplantation</i> , 2013, 27, 348-358.	1.6	14
46	The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population. <i>American Journal of Transplantation</i> , 2019, 19, 2262-2273.	4.7	13
47	High Unbound Mycophenolic Acid Concentrations in a Hematopoietic Cell Transplantation Patient with Sepsis and Renal and Hepatic Dysfunction. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 977-978.	2.0	12
48	Pharmacokinetic-pharmacodynamic modelling of acute terminal pro-B-type natriuretic peptide after doxorubicin infusion in breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 773-783.	2.4	12
49	Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit. <i>Frontiers in Pharmacology</i> , 2018, 9, 1436.	3.5	12
50	CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0062321.	3.2	12
51	Reduced Enterohepatic Recirculation of Mycophenolate and Lower Blood Concentrations Are Associated with the Stool Bacterial Microbiome after Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 372.e1-372.e9.	1.2	12
52	Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing. <i>Pharmacogenomics Journal</i> , 2019, 19, 375-389.	2.0	11
53	Pharmacogenomics education, research and clinical implementation in the state of Minnesota. <i>Pharmacogenomics</i> , 2021, 22, 681-691.	1.3	11
54	Stability of isradipine in an extemporaneously compounded oral liquid. <i>American Journal of Health-System Pharmacy</i> , 1994, 51, 2409-2411.	1.0	10

#	ARTICLE	IF	CITATIONS
55	Prediction of Unbound Mycophenolic Acid Concentrations in Patients After Hematopoietic Cell Transplantation. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 385-390.	2.0	10
56	Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 75-79.	0.9	10
57	Pharmacokinetics of Clofarabine in Patients With High-Risk Inherited Metabolic Disorders Undergoing Brain-Sparing Hematopoietic Cell Transplantation. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 679-686.	2.0	9
58	Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. <i>SpringerPlus</i> , 2015, 4, 32.	1.2	8
59	Early detection of SARS-CoV-2 and other infections in solid organ transplant recipients and household members using wearable devices. <i>Transplant International</i> , 2021, 34, 1019-1031.	1.6	6
60	Fludarabine Pharmacokinetics in Nonmyeloablative Hematopoietic Cell Transplantation (HCT): Association with Engraftment and Neurotoxicity. <i>Blood</i> , 2005, 106, 3673-3673.	1.4	6
61	A cost-effectiveness analysis of pretreatment <i>DPYD</i> and <i>UGT1A1</i> screening in patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI+bevacizumab (FOLFIRI+Bev). <i>Journal of Clinical Oncology</i> , 2020, 38, 168-168.	1.6	6
62	Development and Implementation of In-House Pharmacogenomic Testing Program at a Major Academic Health System. <i>Frontiers in Genetics</i> , 2021, 12, 712602.	2.3	6
63	Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. <i>Pharmacotherapy</i> , 2017, 37, 1366-1373.	2.6	5
64	Comparative Evaluation of Median Versus Youden Index Dichotomization Methods: Exposure-Response Analysis of Mycophenolic Acid and Acyl-Glucuronide Metabolite. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 629-638.	1.6	5
65	Stability of itraconazole in an extemporaneously compounded oral liquid. <i>American Journal of Health-System Pharmacy</i> , 1995, 52, 189-191.	1.0	4
66	Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration. <i>American Journal of Health-System Pharmacy</i> , 1999, 56, 164-169.	1.0	4
67	Concepts of Genomics in Kidney Transplantation. <i>Current Transplantation Reports</i> , 2017, 4, 116-123.	2.0	4
68	Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	4
69	Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities. <i>Clinical Lung Cancer</i> , 2020, 21, e164-e168.	2.6	3
70	Pharmacogenomics in kidney transplant recipients and potential for integration into practice. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1457-1465.	1.5	3
71	Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1035-1044.	2.0	3
72	Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 773.e1-773.e8.	1.2	3

#	ARTICLE	IF	CITATIONS
73	Predictive Value of C-reactive Protein and Albumin for Temporal Within-Individual Pharmacokinetic Variability of Voriconazole in Pediatric Patients Undergoing Hematopoietic Cell Transplantation. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 855-862.	2.0	3
74	Exploring Potential for a Personalized Medicine Approach to Smoking Cessation With an American Indian Tribe. <i>Nicotine and Tobacco Research</i> , 2023, 25, 120-126.	2.6	3
75	A Multi-Marker Test for Analyzing Paired Genetic Data in Transplantation. <i>Frontiers in Genetics</i> , 2021, 12, 745773.	2.3	2
76	Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 543-549.	2.3	2
77	Precision medicine, agriculture, and genome editing: science and ethics. <i>Annals of the New York Academy of Sciences</i> , 2020, 1465, 59-75.	3.8	1
78	Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation. <i>European Journal of Haematology</i> , 2021, 106, 205-212.	2.2	1
79	Perceptions of pharmacogenetic exceptionalism and the implications for clinical management within an electronic health record. <i>Clinical and Translational Science</i> , 0, , .	3.1	1
80	Stability of fluconazole and amino acids in parenteral nutrient solutions. <i>American Journal of Health-System Pharmacy</i> , 1992, 49, 1459-1462.	1.0	0
81	Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions. <i>American Journal of Health-System Pharmacy</i> , 1994, 51, 503-508.	1.0	0
82	Oral Bioavailability of Mycophenolate Mofetil in Patients Undergoing Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Is Poor and Highly Variable.. <i>Blood</i> , 2005, 106, 842-842.	1.4	0
83	Pharmacogenetics of Mycophenolate Mofetil in Patients Undergoing Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2007, 110, 3010-3010.	1.4	0
84	Higher Mycophenolate Dose Requirements in Children Undergoing Hematopoietic Cell Transplant (HCT).. <i>Blood</i> , 2007, 110, 3011-3011.	1.4	0
85	Brain Sparing Conditioning Regimen and Umbilical Cord Blood Transplantation for Inherited High Risk Neurologic Metabolic Diseases.. <i>Blood</i> , 2007, 110, 3009-3009.	1.4	0
86	Comparison of Two Mycophenolate Mofetil Dosing Regimens Following Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2008, 112, 1116-1116.	1.4	0
87	Fludarabine Exposure Is Associated with Increased Treatment Related Mortality after Nonmyeloablative Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2008, 112, 795-795.	1.4	0
88	Association Between Genetic Variants in Immune Response Genes and Outcomes After Hematopoietic Cell Transplantation. <i>Blood</i> , 2011, 118, 3049-3049.	1.4	0
89	Phosphoramidate Mustard As a Biomarker Of Cyclophosphamide Exposure In Adults Receiving Reduced Intensity Conditioning Hematopoietic Cell Transplantation. <i>Blood</i> , 2013, 122, 5461-5461.	1.4	0
90	Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2019, 134, 39-39.	1.4	0

#	ARTICLE	IF	CITATIONS
91	FC033: Genome-Wide Association Meta-Analysis Identifies Novel Loci for Kidney Failure. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0